Sysmex (OTCMKTS:SSMXY) Issues FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.590-0.590 for the period. The company issued revenue guidance of $3.4 billion-$3.4 billion.

Sysmex Price Performance

SSMXY stock opened at $18.65 on Wednesday. The firm has a market capitalization of $11.74 billion, a P/E ratio of 36.37 and a beta of 0.84. Sysmex has a 52 week low of $14.38 and a 52 week high of $29.78. The company has a quick ratio of 2.40, a current ratio of 3.23 and a debt-to-equity ratio of 0.11. The company has a fifty day simple moving average of $19.21 and a two-hundred day simple moving average of $17.58.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Tuesday, August 6th. The company reported $0.11 earnings per share for the quarter. The firm had revenue of $718.13 million during the quarter. Analysts anticipate that Sysmex will post 0.65 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.